-+ 0.00%
-+ 0.00%
-+ 0.00%

Evaxion expands AI-Immunology platform into autoimmune disease drug concepts

PUBT·09/14/2026 12:00:58
Listen to the news
Evaxion expands AI-Immunology platform into autoimmune disease drug concepts
  • Evaxion expanded its AI-Immunology platform into autoimmune diseases, broadening its R&D scope beyond vaccines.
  • Experimental testing began on two treatment concepts: a tolerogenic vaccine using T-cell epitopes, and an autoantibody-binding antigen construct.
  • Initial experimental data is scheduled for presentation at PEGS Europe in Lisbon on Nov. 18, 2026.
  • The program targets disease drivers with high specificity, aiming for higher efficacy and fewer side effects than current symptom-focused therapies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609140800OMX_____CNEWS_EN_GNW1001262521_en) on September 14, 2026, and is solely responsible for the information contained therein.